Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

In Alzheimer's disease (AD), amyloid β-protein (Aβ) production by regulated intramembrane proteolysis is crucial for pathogenicity. An unusual intramembrane cleavage generates various Aβ ...

However, hereditary amyloidosis happens when you have a genetic mutation that causes a change in how amyloid proteins fold.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...

Gantenerumab helps eliminate one of the neurological hallmarks of Alzheimer’s, called amyloid plaques. For some participants, gantenerumab reduced their risk of developing the disease by more ...

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease. Nature Medicine , 2025; DOI: 10.1038/s41591-025-03574-1 Cite This Page : ...

The findings suggest -- for the first time in a clinical trial -- that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer's ...